

LEXICON PHARMACEUTICALS, INC.

Form SC 13G/A

October 14, 2015

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No. 1)

LEXICON PHARMACEUTICALS, INC.

(Name of Issuer)

Common Stock
(Title of Class of Securities)

528872302

(CUSIP Number)

September 30, 2015
Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

/x/ Rule 13d-1(b)
 / / Rule 13d-1(c)
 / / Rule 13d-1(d)

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

1. Names of Reporting Persons and I.R.S. Identification No.

UBS Group AG (for the benefit and on behalf of the UBS Global Asset Management division of UBS Group AG, see Item 7)

98-0186363

Edgar Filing: LEXICON PHARMACEUTICALS, INC. - Form SC 13G/A

2. Check the Appropriate Box if a Member of a Group

a / /
b / / See Item 8 of attached schedule

3. SEC USE ONLY

4. Citizenship or Place of Organization

Switzerland

Number of	5. Sole Voting Power	10,514,894
Shares Bene-	6. Shared Voting Power	0
ficially	7. Sole Dispositive Power	0
Owned by Each	8. Shared Dispositive Power	11,069,517

Reporting
Person With:

9. Aggregate Amount Beneficially Owned by Each Reporting Person:

11,069,517*

10. Check if the Aggregate Amount in Row 9 Excludes Certain
Shares / /

11. Percent of Class Represented by Amount in Row 9

10.68%

12. Type of Reporting Person

HC

The Reporting Person disclaims beneficial ownership of such securities pursuant to Rule 13d-4 under the Securities Exchange Act of 1934. In accordance with SEC Release No. 34-39538 (January 12, 1998), this filing reflects the securities beneficially owned by the UBS Global Asset Management division of UBS Group AG and its subsidiaries and affiliates on behalf of its clients. This filing does not reflect securities, if any, beneficially owned by any other division of UBS Group AG.

1
Names of Reporting Persons
I.R.S. Identification Nos. of above persons (entities only).

UBS Americas Inc.
06-1595848

2

Edgar Filing: LEXICON PHARMACEUTICALS, INC. - Form SC 13G/A

Check the Appropriate Box if a Member of a Group (See Instructions)

a / /

b / / See Item 8 of attached schedule.

3

SEC USE ONLY

4

Citizenship or Place of Organization - Delaware

Number of	5. Sole Voting Power	5,988,537
Shares Bene-	6. Shared Voting Power	0
ficially	7. Sole Dispositive Power	0
Owned by Each	8. Shared Dispositive Power	6,090,113

Reporting
Person With:

9

Aggregate Amount Beneficially Owned by Each Reporting Person

6,090,113 Shares*

10

Check if the Aggregate Amount in Row (9) Excludes Certain
Shares (See Instructions)

11

Percent of Class Represented by Amount in Row (9)

5.88%

12

Type of Reporting Person (See Instructions)

HC

The Reporting Person disclaims beneficial ownership of such securities pursuant to Rule 13d-4 under the Securities Exchange Act of 1934. In accordance with SEC Release No. 34-39538 (January 12, 1998), this filing reflects the securities beneficially owned by the UBS Global Asset Management division of UBS Group AG and its subsidiaries and affiliates on behalf of its clients. This filing does not reflect securities, if any, beneficially owned by any other division of UBS Group AG.

1. Names of Reporting Persons and I.R.S. Identification No.

UBS Global Asset Management (Americas) Inc.

36-3664388

2. Check the Appropriate Box if a Member of a Group

Edgar Filing: LEXICON PHARMACEUTICALS, INC. - Form SC 13G/A

a / /
b / / See Item 8 of attached schedule

3. SEC USE ONLY

4. Citizenship or Place of Organization

Delaware

Number of 5. Sole Voting Power 5,963,960
Shares Bene- 6. Shared Voting Power 0
ficially 7. Sole Dispositive Power 0
Owned by Each 8. Shared Dispositive Power 6,065,536

Reporting
Person With:

9. Aggregate Amount Beneficially Owned by Each Reporting Person:

6,056,536 shares*

10. Check if the Aggregate Amount in Row 9 Excludes Certain
Shares / /

11. Percent of Class Represented by Amount in Row 9

5.85%

12. Type of Reporting Person

IA

The Reporting Person disclaims beneficial ownership of such securities pursuant to Rule 13d-4 under the Securities Exchange Act of 1934. In accordance with SEC Release No. 34-39538 (January 12, 1998), this filing reflects the securities beneficially owned by the UBS Global Asset Management division of UBS Group AG and its subsidiaries and affiliates on behalf of its clients. This filing does not reflect securities, of any, beneficially owned by any other division of UBS Group AG.

Cusip 528872302

Item 1(a). Name of Issuer:

LEXICON PHARMACEUTICALS, INC.

Item 1(b). Address of Issuer's Principal Executive Offices:

Edgar Filing: LEXICON PHARMACEUTICALS, INC. - Form SC 13G/A

8800 TECHNOLOGY FOREST PLACE
THE WOODLANDS, TX 77381

Item 2(a) Name of Persons Filing:
UBS Group AG

Item 2(b) Address of Principal Business Office or, if none,
Residence:

UBS Group AG's principal business office is:
Bahnhofstrasse 45
Zurich, Switzerland

Item 2(c) Citizenship:
Incorporated by reference to Item 4 of the cover pages.

Item 2(d) Title of Class of Securities:
Common Stock (the "Common Stock")

Item 2(e) CUSIP Number:
528872302

Item 3. Type of Person Filing:

If this statement is filed pursuant to Rules 13d-1(b), or
13d-2(b) or (c), check whether the person filing is a:

- / / Broker or dealer registered under Section 15 of the Act;
- / / Bank as defined in Section 3(a)(6) of the Act;
- / / Insurance company as defined in Section 3(a)(19) of the Act;
- / / Investment company registered under Section 8 of the
Investment Company Act of 1940;
- / / An investment adviser in accordance with Rule 13d-1(b)(1)
(ii)(E);
- / / An employee benefit plan or endowment fund in accordance
with Rule 13d-1(b)(1)(ii)(F);
- /X/ A parent holding company or control person in accordance
with Rule 13d-1(b)(1)(ii)(G);
- / / A savings association as defined in Section 3(b) of the
Federal Deposit Insurance Act (12 U.S.C. 1813);
- / / A church plan that is excluded from the definition of an
investment company under Section 3(c)(14) of the
Investment Company Act of 1940;
- / / A non-U.S. institution in accordance with Rule 240.13d-1
(b)(1)(ii)(J);
- / / Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
If filing as a non-U.S. institution in accordance with
Rule 240.13d-1(b)(1)(ii)(J), please specify the type of
institution.

Item 4 (a)-(c)(iv). Ownership:
Incorporated by reference to Items 5-11 of the cover pages.

The amount of shares beneficially owned includes shares
of common stock (CUSIP 528872302) issuable upon conversion of

Edgar Filing: LEXICON PHARMACEUTICALS, INC. - Form SC 13G/A

5.25% Convertible Senior Notes due 2021 (CUSIP 528872AA2).

Cusip 528872302

Item 5. Ownership of Five Percent or Less of a Class:

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following / /.

Item 6. Ownership of More than Five Percent on Behalf of Another Person:

Accounts managed on a discretionary basis by the UBS Global Asset Management division of UBS Group AG (UBS Global AM) have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Common Stock. To the best of our knowledge, no account holds more than 5 percent of the outstanding Common Stock.

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company:

Identification: UBS Global Asset Management (Americas) Inc.
Classification: IA

In addition to UBS Group AG, the following UBS Global AM affiliates and subsidiaries are part of the UBS Global Asset Management division included in this filing: UBS AG, UBS Global Asset Management (Americas) Inc., UBS Global Asset Management Trust Company, UBS Global Asset Management (Canada) Inc., UBS Global Asset Management (Australia) Ltd., UBS Global Asset Management (Hong Kong) Limited, UBS Global Asset Management (Japan) Ltd., UBS Global Asset Management (Singapore) Ltd., UBS Global Asset Management (Taiwan) Ltd., UBS Global Asset Management (Deutschland) GmbH, UBS Global Asset Management (Italia) SGR SpA, UBS Global Asset Management (UK) Ltd., UBS Global Asset Management Life Limited, Hana Asset Management Co., Ltd., and CCR Asset Management S.A.

UBS Group AG acquired UBS AG through the completion of a share transfer offer on 28 November 2014 in which the shareholders of UBS AG became shareholders of UBS Group AG and their shares in UBS AG were transferred to UBS Group AG. As a result, UBS Group AG controls UBS AG.

Item 8

UBS Global AM is composed of wholly-owned subsidiaries and branches of UBS Group AG. UBS Group AG is reporting direct and indirect beneficial ownership of holdings. None of the reporting persons affirm the existence of a group within the meaning of Rule 13d-5(b)(1).

Cusip 528872302

Item 9 Notice of Dissolution of Group:
Not Applicable

Item 10 Certification:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: October 12, 2015

UBS Group AG

By: /s/ Mark F. Kemper
Mark F. Kemper
Attorney-in-Fact
pursuant to Power of Attorney, attached as Exhibit 1,
for the UBS Global Asset Management division
of UBS Group AG

By: /s/ Michael J. Calhoun
Michael J. Calhoun
Attorney-in-Fact
pursuant to Power of Attorney, attached as Exhibit 1,
for the UBS Global Asset Management division
of UBS Group AG

EXHIBIT INDEX

Exhibit Number	Exhibit Description
1	Power of Attorney dated as of January 12, 2015

EXHIBIT 1

Edgar Filing: LEXICON PHARMACEUTICALS, INC. - Form SC 13G/A

POWER OF ATTORNEY

Each of the following representatives of UBS Global Asset Management (Americas) Inc. is hereby appointed as agent and attorney-in-fact with power and authority to sign US Regulatory Filings, including Schedule 13G and Form 13F, on behalf of UBS Group AG and its affiliates in the UBS Global Asset Management division:

Joseph Allessie
James Barling
Michael J. Calhoun
Mark F. Kemper
John Moore
Barry Mullen
Jennifer Wiley

All prior powers of attorney relating to the subject matter of this Power of Attorney are hereby revoked. This Power of Attorney is limited to the circumstances set forth herein and may be revoked, in whole or in part, at any time. If a person identified above ceases to perform services for UBS Global Asset Management for any reason, this Power of Attorney shall be automatically revoked with respect to that person. Nothing in this Power of Attorney is intended to limit the authority of any other persons to sign documents relating to the subject matter hereof to the extent permitted by UBS Group Policy or otherwise.

APPROVED:

Date: As of January 12, 2015

/s/ Mario Cueni
Mario Cueni
UBS Global Asset Management
General Counsel
Group Managing Director

/s/ Shawn Lytle
Shawn Lytle
UBS Global Asset Management
Head of Americas
Group Managing Director